Examiner: ORWIG, KEVIN S

Tech Center 3900 • Art Units: 1611 1658 3991

This examiner grants 26% of resolved cases

Analysis

Kevin S Orwig serves in Tech Center 3900 and Art Unit 1611, with 709 resolved cases. The allowance rate is 25.4%, which is low and suggests a challenging path for applicants. The median days to allowance is 1536, indicating that the cases that do reach allowance take a long time to do so. This 1536-day figure, combined with the 25.4% success rate, highlights the rigorous nature of examination in this unit.

However, the interview lift is a substantial 40.2%. This 40.2% lift is a key metric in the profile, as it increases the likelihood of success compared to the 25.4% baseline. For the 709 resolved cases, this data suggests that direct engagement is an effective strategy for overcoming rejections. Practitioners should prioritize interviews during the 1536-day median pendency to take advantage of this 40.2% lift and improve their chances in a challenging environment.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

25.5%

Allow Rate

-34.5% vs TC avg

729

Total Applications

+40.1%

Interview Lift

1536

Avg Prosecution Days

Based on 711 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%

§101 Eligibility

16.3%

§102 Novelty

40.2%

§103 Obviousness

25.6%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18320145	TUMOR-SPECIFIC MINICIRCLES FOR CANCER SCREENING	Non-Final OA	The Board of Trustees of the Leland Stanford Junior University
18711216	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	Non-Final OA	Merck Sharp & Dohme LLC
18662935	COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE	Non-Final OA	Takeda Pharmaceutical Company Limited
18282152	REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V	Non-Final OA	ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
18698649	Biologically Active Collagen Hybridizing Peptides	Non-Final OA	3HELIX, INC.
18574406	PEPTIDE HAVING ANTIDIABETIC ACTIVITY AND USE THEREOF	Final Rejection	MEDI&GENE INC.
18491078	Nucleic Acid Molecules Encoding Indoleamine 2,3-Dioxygenase-2	Non-Final OA	LANKENAU INSTITUTE FOR MEDICAL RESEARCH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy